Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
10.84
+0.64 (6.27%)
At close: Jul 2, 2026, 4:00 PM EDT
10.85
+0.01 (0.09%)
After-hours: Jul 2, 2026, 7:57 PM EDT
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
121
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
| Dec 31, 2021 | 13.62M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Xencor | 97.36M |
| Kura Oncology | 71.64M |
| Lexicon Pharmaceuticals | 69.64M |
| Avalo Therapeutics | 59.00K |
SLDB News
- 25 days ago - Solid Biosciences Transcript: AGM 2026 - Transcripts
- 26 days ago - Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright - TheFly
- 4 weeks ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Solid Biosciences price target lowered to $16 from $17 at Wedbush - TheFly
- 7 weeks ago - Solid Biosciences price target raised to $18 from $17 at Piper Sandler - TheFly